MANNKIND CORP Sales Revenue, Goods, Net (Deprecated 2018-01-31)
MANNKIND CORP (MNKD) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $3.40 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-05-09
- MANNKIND CORP sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $3.40M, a 184.45% increase year-over-year.
- MANNKIND CORP sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $1.20M, a 9.23% decline year-over-year.
- MANNKIND CORP sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $1.98M, a 245.72% increase year-over-year.
- MANNKIND CORP sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $1.55M.
- MANNKIND CORP sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $9.19M, a 385.07% increase from fiscal 2016.
- MANNKIND CORP sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $1.90M.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $3.40M 10-Q · filed 2018-05-09 | $4.60M derived: sum of 2 quarters · filed 2018-05-09 | $6.58M derived: sum of 3 quarters · filed 2018-05-09 | $8.13M derived: sum of 4 quarters · filed 2018-05-09 |
| 2017-12-31 | $1.20M 10-K · filed 2018-02-27 | $3.18M derived: sum of 2 quarters · filed 2018-02-27 | $4.73M derived: sum of 3 quarters · filed 2018-02-27 | $9.19M 10-K · filed 2018-02-27 |
| 2017-09-30 | $1.98M 10-Q · filed 2017-11-07 | $3.53M derived: sum of 2 quarters · filed 2017-11-07 | $4.73M 10-Q · filed 2017-11-07 | $6.05M derived: sum of 4 quarters · filed 2018-05-09 |
| 2017-06-30 | $1.55M 10-Q · filed 2017-08-07 | $2.75M 10-Q · filed 2017-08-07 | $4.07M derived: sum of 3 quarters · filed 2018-05-09 | $4.64M derived: sum of 4 quarters · filed 2018-05-09 |
| 2017-03-31 | $1.20M 10-Q · filed 2018-05-09 | $2.52M derived: sum of 2 quarters · filed 2018-05-09 | $3.09M derived: sum of 3 quarters · filed 2018-05-09 | |
| 2016-12-31 | $1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $1.90M derived: sum of 2 quarters · filed 2018-02-27 | $1.90M 10-K · filed 2018-02-27 | |
| 2016-09-30 | $573.00K 10-Q · filed 2017-11-07 | $573.00K 10-Q · filed 2017-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |